Patents by Inventor Thomas Decoene

Thomas Decoene has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240191270
    Abstract: The present invention is in the technical field of synthetic biology and metabolic engineering. More particularly, the present invention is in the technical field of metabolically engineered cells and use of said cell in a cultivation, preferably a fermentation. The present invention describes a cell for the production of a compound. The cell comprises a pathway for the production of the compound, which can be a disaccharide, oligosaccharide and/or a Neu(n)Ac-containing bioproduct, wherein (n) is 4, 5, 7, 8 or 9 or a combination thereof. The cell is metabolically engineered for enhanced synthesis of acetyl-Coenzyme A. The invention also resides in a method of producing such compound by cultivation, preferably a fermentation, with such a cell.
    Type: Application
    Filed: April 15, 2022
    Publication date: June 13, 2024
    Inventors: Joeri Beauprez, Pieter Coussement, Thomas Decoene
  • Publication number: 20240076704
    Abstract: Described is a method of producing bioproducts by fermentation with a genetically modified cell, as well as to the genetically modified cell used in the method. The cell is genetically modified to produce a bioproduct and is further genetically modified by reducing the expression of at least one endogenous membrane protein encoding gene and/or mutating the expression of the endogenous membrane protein.
    Type: Application
    Filed: October 14, 2020
    Publication date: March 7, 2024
    Inventors: Joeri Beauprez, Pieter Coussement, Nausicaä Lannoo, Gert Peters, Kristof Vandewalle, Annelies Vercauteren, Sofie Aesaert, Thomas Decoene
  • Publication number: 20230416796
    Abstract: The disclosure is in the technical field of synthetic biology and metabolic engineering. Described is the use of a new type of galactosyltransferases for the production of a galactosylated di- or oligosaccharide. The disclosure also describes methods for the production of a galactosylated di- or oligosaccharide as well as the purification of the di- or oligosaccharide. Furthermore, the disclosure is in the field of cultivation or fermentation of metabolically engineered cells. The disclosure provides a cell metabolically engineered for production of a galactosylated di- or oligosaccharide.
    Type: Application
    Filed: February 10, 2023
    Publication date: December 28, 2023
    Inventors: Sofie Aesaert, Joeri Beauprez, Pieter Coussement, Thomas Decoene, Nausicaä Lannoo, Gert Peters, Kristof Vandewalle, Annelies Vercauteren
  • Publication number: 20230313253
    Abstract: The disclosure is in the technical field of synthetic biology and metabolic engineering. More particularly, the disclosure is in the technical field of cultivation or fermentation of metabolically engineered cells. The disclosure describes a method for the production of a di- or oligosaccharide with an N-acetylglucosamine at the reducing end by a cell as well as the purification of the di- or oligosaccharide from the cultivation. Furthermore, the disclosure provides a cell metabolically engineered for production of a di- or oligosaccharide with an N-acetylglucosamine at the reducing end.
    Type: Application
    Filed: August 10, 2021
    Publication date: October 5, 2023
    Inventors: Sofie Aesaert, Joeri Beauprez, Pieter Coussement, Thomas Decoene, Nausicaä Lannoo, Gert Peters, Kristof Vandewalle, Annelies Vercauteren
  • Publication number: 20230313252
    Abstract: The disclosure is in the technical field of synthetic biology and metabolic engineering. More particularly, the disclosure is in the technical field of metabolically engineered cells and use of the cells in a cultivation or fermentation. The disclosure describes a metabolically engineered cell and a method by cultivation or fermentation with the cell for production of a sialylated di- and/or oligosaccharide. The metabolically engineered cell comprises a pathway for production of the sialylated di- and/or oligosaccharide and is modified for expression and/or overexpression of multiple coding DNA sequences encoding one or more isoproteins that catalyze the same chemical reaction. Furthermore, the disclosure provides for purification of the sialylated di- and/or oligosaccharide from the cultivation.
    Type: Application
    Filed: August 10, 2021
    Publication date: October 5, 2023
    Inventors: Sofie Aesaert, Joeri Beauprez, Pieter Coussement, Thomas Decoene, Nausicaä Lannoo, Gert Peters, Kristof Vandewalle
  • Publication number: 20230287470
    Abstract: This disclosure is in the technical field of synthetic biology and metabolic engineering. More particularly, this disclosure is in the technical field of cultivation or fermentation of metabolically engineered cells. This disclosure provides a method for the production of a mixture of at least two different oligosaccharides by a cell as well as the purification of at least one of the oligosaccharides from the cultivation. In addition, this disclosure provides a method for the production of a mixture of at least two different oligosaccharides by a metabolically engineered cell as well as the purification of at least one of the oligosaccharides from the cultivation.
    Type: Application
    Filed: August 10, 2021
    Publication date: September 14, 2023
    Inventors: Sofie Aesaert, Joeri Beauprez, Pieter Coussement, Thomas Decoene, Nausicaä Lannoo, Gert Peters, Kristof Vandewalle, Annelies Vercauteren
  • Publication number: 20230279403
    Abstract: The disclosure is in the technical field of synthetic biology and metabolic engineering. More particularly, the disclosure is in the technical field of cultivation or fermentation of metabolically engineered cells. The disclosure describes a cell metabolically engineered for production of an alpha-1,3 glycosylated form of fucose-alpha1,2-galactose-R (Fuc-a1,2-Gal-R). Furthermore, the disclosure provides a method for the production of an alpha-1,3 glycosylated form of Fuc-a1,2-Gal-R by a cell as well as the purification of the alpha-1,3 glycosylated form Fuc-a1,2-Gal-R from the cultivation.
    Type: Application
    Filed: August 10, 2021
    Publication date: September 7, 2023
    Inventors: Sofie Aesaert, Joeri Beauprez, Pieter Coussement, Thomas Decoene, Nausicaä Lannoo, Gert Peters, Kristof Vandewalle, Annelies Vercauteren
  • Publication number: 20230265399
    Abstract: The disclosure is in the technical field of synthetic biology and metabolic engineering. More particularly, the disclosure is in the technical field of cultivation or fermentation of metabolically engineered cells. The disclosure describes a cell metabolically engineered for production of a mixture of at least four different neutral non-fucosylated oligosaccharides. Furthermore, the disclosure provides a method for the production of a mixture of at least four different neutral non-fucosylated oligosaccharides by a cell as well as the purification of at least one of the oligosaccharides from the cultivation.
    Type: Application
    Filed: August 10, 2021
    Publication date: August 24, 2023
    Inventors: Sofie Aesaert, Joeri Beauprez, Pieter Coussement, Thomas Decoene, Nausicaä Lannoo, Gert Peters, Kristof Vandewalle, Annelies Vercauteren
  • Publication number: 20230212628
    Abstract: The present invention is in the technical field of synthetic biology and metabolic engineering. More particularly, the present invention is in the technical field of fermentation of metabolically engineered host cells. The present invention describes a method of making sialylated oligosaccharide by fermentation with a genetically modified cell, as well as to the genetically modified cell used in the method. The genetically modified cell comprises at least one nucleic acid sequence coding for an enzyme involved in sialylated oligosaccharide synthesis and at least one nucleic acid expressing a membrane protein.
    Type: Application
    Filed: December 18, 2020
    Publication date: July 6, 2023
    Inventors: Joeri Beauprez, Pieter Coussement, Thomas Decoene, Annelies Vercauteren
  • Publication number: 20220396817
    Abstract: The present disclosure is in the technical field of synthetic biology and metabolic engineering. The disclosure provides engineered viable bacteria. In particular, the disclosure provides viable bacteria with reduced cell wall biosynthesis additionally modified for production of glycosylated product. The disclosure further provides methods of generating viable bacteria and uses thereof. Furthermore, the disclosure in the technical field of fermentation of metabolically engineered microorganisms producing glycosylated product.
    Type: Application
    Filed: February 12, 2021
    Publication date: December 15, 2022
    Inventors: Sofie Aesaert, Joeri Beauprez, Pieter Coussement, Thomas Decoene, Nausicaä Lannoo, Gert Peters, Kristof Vandewalle